<p>Visit <a href="http://www.MorningCommutePodcast.com/NSCLC3" rel="nofollow">MorningCommutePodcast.com/NSCLC3</a> to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations.  At the time this podcast was recorded, cemiplimab was pending approval.</p>

Visit MorningCommutePodcast.com/NSCLC3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations. At the time this podcast was recorded, cemiplimab was pending approval.

<p>Visit <a href="http://www.MorningCommutePodcast.com/NSCLC3" rel="noopener noreferrer">MorningCommutePodcast.com/NSCLC3</a> to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations.&nbsp; At the time this podcast was recorded, cemiplimab was pending approval.</p>

S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon?

Our @Point of Care Oncology Podcasts have healthcare experts discussing and providing information related to oncology diagnosis, treatment, management, and other important information.

Share S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon?

Sign up to save your podcasts

S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon?

S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon?